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Abbreviations 
3-box: Cul3-interaction box 
AdRP : Autosomal dominant Retinitis Pigmentosa 
ATP: Adenosine tri-phosphate 
RP: Retinitis Pigmentosa 
BHA: Butylated hydroxyanisole 
BTB/POZ: Bric-à-brac, Tramtrack and Broad complex/Poxviruses and Zinc finger 
CHAPS: 3-[(3-Cholamidopropyl)dimethylammonio] propanesulfonate 
CRL: Cullin Ring Ligase 
Cul: Cullin 
E1: Ubiquitin Activating Enzyme 
E2: Ubiquitin Conjugating Enzyme 
E3: Ubiquitin Ligase 
EDTA: ethylenediaminetetraacetic acid 
FSCN2: FASCIN, retinal 
GFP: Green Fluorescent Protein 
IP: Immunoprecipitation 
KLHL7: Kelch-like 7 
KO: Knock-out 
LAMP1: Lysosome-Associated Membrane Protein 1 
LC3: Microtuble-associated proteins1A/1B, Light Chain 3A 
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lf: Long form 
MEF: Mouse Embryonic Fibroblast 
MT: Mutant  
NEAA: Non-Essential Amino Acids 
PCR: Polymerase Chain Reaction 
SCF: Skp1-Cullin 1-F-box protein 
SDS-PAGE: Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
sf: Short form 
snRNA: small nuclear RNA 
snRNP: small nuclear ribonucleoprotein 
tBHQ: tertiary butylhydroquinone 
Tg: Tapsigargin 
TTF: Tail-tip fibroblast 
Ub: Ubiquitin 
UPS: Ubiquitin Proteasome System 
WCL: Whole Cell Lysate 
WT: Wild-type 
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General Introduction 
Covalent attachment of ubiquitin (Ub) onto proteins is involved in the regulation of a 
wide array of cellular phenomena, ranging from the cell cycle progression to stress 
response and DNA damage repair33,67. When a protein is targeted for ubiquitination, a 
Ub molecule is attached onto a lysine residue within the substrate protein. There are 
seven lysine residues in a Ub molecule, and various forms of poly-Ub chains can be 
formed by the covalent attachment of Ub molecules via one of the seven lysine residues 
or the N terminus of the first Ub molecule and the C terminus of the second.  
The difference in modes of ubiquitination is known to exhibit different 
regulations on the substrate protein. The most well studied is the Lys48-linked poly-Ub 
chain, formed from multiple Ub molecules conjugated via the 48th Lysine of the Ub 
molecules. When the Lys48-linked poly-Ub chain consisting of more than four Ub 
molecules is conjugated onto the substrate protein, it is known to act as a degradation 
signal, which is recognized by the proteasome and consequently leads to the 
degradation of the ubiquitinated protein33,68. Lys63-linked poly-Ub chains are involved 
in non-proteolytic regulation such as signal transduction and damaged DNA repair68 and 
autophagy-mediated protein degradation63. The attachment of a single, mono-Ub is also 
known to have regulatory properties, and has been shown to affect the localization or 
trafficking of the conjugated substrate. Other modes of the Ub chain are present in 
eukaryotic cells92, but the functions of each form are not yet characterized in detail.  
In the ubiquitination reaction, Ub is first activated by the Ub-activating 
enzyme E1, and then carried by the Ub-conjugating enzyme E2 to the Ub ligase E3, and 
is attached onto a lysine residue of the specific substrate of the E3s33,67. The substrate 
specificity of this pathway is determined by the vast number of E3s, that each 
ubiquitinates its specific target. E3s consist of a diverse group of proteins, which can be 
characterized by several domains. E3s that contain the HECT domain exhibits a distinct 
role in catalysis, transferring Ub onto the substrate, whereas E3s with the RING-finger 
and U-box domains function by facilitating the ubiquitination reaction by recruiting Ub 
conjugated E2 into close proximity to the substrate to promote ubiquitination. Among 
the RING ligases, some are known to have sufficient activity on its own, however, some 
functions by forming complexes such as the Cullin-RING ligases (CRLs), the largest 
subclass of E3s. 
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CRLs are multi-subunit complexes where the enzymatic core Roc1/Rbx1, and 
substrate recognition modules each assemble onto the C- and N-terminus of a Cullin 
(Cul) protein. Currently, 7 members of the Cul family protein (Cul1, Cul2, Cul3, Cul4A, 
Cul4B, Cul5 and Cul7)9,20,38,66,87 are reported to act as the scaffold of ubiquitin ligase 
complexes, each partnering with individual protein families as the substrate recognition 
module. The most well characterized CRL is the SCF Ub ligase, comprised of Cul1, 
Roc1, an F-box family protein and Skp1. The F-box protein, that recruits the substrate, 
binds to the adaptor protein Skp1, which in turn binds onto Cul124,64,86,96.  
In Cul3-based CRLs, BTB (Bric-à-brac, Tramtrack and Broad complex) 
family proteins, that contain the BTB/POZ (poxviruses and zinc finger) domain are 
employed as the substrate adaptor, instead of F-box proteins27,28,69,91. There are more 
than 180 BTB proteins encoded in the human genome75, and some of them have been 
related to substrate-targeting in Cul3 complexes. Taking into account of the vast number 
of BTB proteins, only a fraction of them has been shown to act in Cul3-based CRLs, 
and the function of only a handful of BTBs is known.  
Of the BTBs involved in ubiquitination processes, the BTB-Kelch protein 
Keap1 is the best characterized. By regulating the turnover of the transcription factor 
Nrf2, Keap1 has an important role in the cellular defense mechanism for oxidative and 
xenobiotic stresses37,45. Another two BTB-Kelch proteins, KLHL9 and KLHL13 are 
involved in the cell cycle by targeting Aurora B, thereby regulating cytokinesis76. The 
emerging roles of BTB family proteins, and the discovery of mutations in BTB proteins 
that are responsible for diseases, such as gigaxonin for giant axonal neuropathy patients7 
and KLHL9 in autosomal dominant distal myopathy15, have set forth the importance of 
BTB proteins. 
Recently, three disease-causing missense mutations in the BACK domain of 
KLHL7, a BTB-Kelch protein, were found in patients with autosomal dominant 
Retinitis Pigmentosa (adRP)25,36. RP are a genetically heterogeneous group of 
progressive retinal dystrophies, resulting in degeneration of rod and cone photoreceptors. 
Patients experience night blindness and visual field loss, often leading to complete 
blindness. RP can be inherited in an autosomal dominant, autosomal recessive, and 
X-linked manner18,31. However, the functions and regulation of KLHL7 is not yet 
understood. 
In this study I have aimed to elucidate the molecular and physiological 
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Chapter I 
The Functions of KLHL7 in the Ubiquitin System 
and the Effects of its Mutations 
1.1 Summary 
Substrate specific protein degradation mediated by the Ub proteasome system (UPS), is 
crucial for the proper function of the cell. Proteins are specifically recognized and 
ubiquitinated by the E3 ligases, and are then degraded by the proteasome. BTB proteins 
act as the substrate recognition subunit that recruits their cognate substrates to the 
Cul3-based multi-subunit E3s. Recently, it was reported that missense mutations in 
KLHL7, a BTB-Kelch protein, are related to adRP. However, the involvement of 
KLHL7 in the UPS and the outcome of the adRP causative mutations were unknown. In 
this study, I show that KLHL7 forms a dimer, assembles with Cul3 through its BTB and 
BACK domains, and exerts E3 activity. Lys48- but not Lys63-linked poly-ubiquitin 
chain co-localized with KLHL7, which increased upon proteasome inhibition 
suggesting that KLHL7 mediate protein degradation via UPS. An adRP causative 
missense mutation in the BACK domain of KLHL7 attenuated only the Cul3 interaction 
but not dimerization. Moreover, the incorporation of the mutant as a hetero dimer in 
Cul3-KLHL7 complex diminished the E3 ligase activity. Together, these results suggest 
that KLHL7 constitutes a Cul3-based E3 and that the disease-causing mutation inhibits 
ligase activity in a dominant negative manner, which may lead to inappropriate 
accumulation or regulations of the substrates targeted for ubiquitination by KLHL7. 
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1.2 Introduction 
Through linage analysis of patients with RP, three mutations in the BACK domain of 
the BTB protein KLHL7 were reported to be responsible for adRP25. Studies have 
shown that BTB proteins bind to Cul3 to form Cul3-based CRLs though the BTB 
domain and the adjacent ‘3-box (Cul3-interactin box)’ region, an element involved in 
facilitating this interaction99, which is partially contained in the BACK domain. Whilst 
interacting with Cul3, BTB proteins recruit substrates with their additional 
protein-protein interaction domain, such as the Kelch and MATH domains. 
The structures of Cul3, and its complex are still unsolved, and what 
conformation BTB proteins take within the complexes is still a subject for debate. BTB 
proteins have been reported to form homo dimers, and the structures of several BTB 
homo dimers such as SPOP and Keap1, which are known to interact with a single 
substrate protein as a homo dimer, have been previously reported60,99. However, the 
structure of full BTB proteins in conjunction with Cul3 is not yet resolved. Furthermore, 
Cullin proteins have also been reported to form dimers12,89, comprehensively suggesting 
the possibility that Cullin complexes contain two sets of Cullin-BTBs. The elucidation 
of the possible structures and forms of Cullin complexes will be a key into 
understanding the efficiency of substrate recruitment and its sequential ubiquitination. 
To understand the molecular functions of KLHL7, here, I examined whether 
KLHL7 forms Cul3-based CRLs, and its involvement in protein degradation systems. 
Furthermore, I also investigated the effects of the adRP causative mutations in the 
formation and activity of Cul3-KLHL7 E3 ligase. Here, I report that KLHL7 forms 
Cul3-KLHL7 Ub E3 ligase in cells and that an adRP causative mutation, A153V, leads 
to the attenuation of the E3 ligase activity of Cul3-KLHL7 in a dominant negative 
manner. These results provide molecular insights into the function of KLHL7 and the 
outcome of an adRP-causative mutation. 
8
1.3 Materials and Methods 
Expression Plasmids 
Epitope-tagged full length KLHL7 DNA was amplified from human placenta cDNA 
library using Phusion DNA polymerase (Finnzymes) and cloned into EcoRI and NotI 
sites of pcDNA3 or pEFBOS (-) vectors. GFP-tagged constructs were cloned into 
pEGFP (Clontech) vector. Cul3 and Ub were generated likewise, and cloned into EcoRI 
and XhoI sites. Deletion mutants of KLHL7 were generated by a PCR-based method 32. 
The S150N, A153V and A153T amino-acid substitutions were introduced by 
Quick-Change site-directed mutagenesis method using overlapping primers (Table 1). 
The PCR amplified coding regions of Cul3, KLHL7 (wild-type and mutants) and Ub 
were verified by sequence analyses. LAMP1 DNA sequence inserted into pCS4 
mCherry vector was used as the lysosome marker. 
Cell Culture, Transfection and Treatment 
HCT116 cells were cultured in Dulbecco’s modified Eagle’s medium (low glucose) 
(WAKO) supplemented with 10% fetal bovine serum, 1% Non-Essential Amino Acids 
Solution (NEAA) (Gibco) and 1% penicillin streptomycin (Gibco) in a 37°C incubator 
with 5% CO2. HeLa cells were cultured as above without NEAA. ATG5+/+: GFP-LC3 
and ATG5-/-: GFP-LC3 MEFs49 were cultured in growth medium without NEAA, 
supplemented with 0.8% Puromycin. Transfections were carried out using FuGENE 6 
Transfection reagent (Roche), Lipofectamine 2000 (Invitrogen) or Multifectam 
(Promega) according to the manufacturers’ specifications. For proteasome inhibition, 
cells were treated with MG132 (Z-Leu-Leu-Leu-H) (Peptide institute) for 1 hr at 20 µM. 
For lysosome inhibition, cells were treated with NH4Cl (Wako) for 1 hr at 10 µM. 
Antibodies 
Antibodies used in this study are described in Table 2. Polyclonal anti-Cul3 antibody 
was raised using recombinant His-tagged Cul3. Anti-Roc1 rabbit polyclonal antibody 
has previously been described41. Peroxidase-conjugated anti-rabbit and anti-mouse 
antibodies (Jackson Immuno Research Laboratory) were used as secondary antibodies. 
Alexa Fluor 488 and Alexa Fluor 568 conjugated anti-rabbit and anti-mouse antibodies 
(Invitrogen Molecular Probes) were used for immunocytocheimcal analyses. 
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Immunoprecipitation and Immunoblot Analysis 
Cells were lysed with ice cold lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 
mM Ethylenediaminetetraacetic acid (EDTA), 0.5% CHAPS 
(3-[(3-Cholamidopropyl)dimethylammonio]propanesulfonate) (Sigma), 1 mM 
dithiothreitol (DTT). The supernatant was subjected to immunoprecipitation with 
anti-FLAG M2 agarose or anti-HA agarose beads (Sigma) and incubated at 4°C 
overnight. The beads were then washed with lysis buffer containing 750 mM NaCl and 
0.2% CHAPS. The protein samples were added to SDS sample buffer, boiled for 5 min, 
and immunoblotted using Western Lightning Plus-EDL reagent (Perkin Elmer). 
Immunofluorescence Analysis 
Cells were cultured on coverslips and were transfected with various expression plasmids. 
The cells were fixed in 4% paraformaldehyde in PBS for 10 min, permeabilized and 
blocked in 0.5% Triton X-100, 5% BSA in PBS for 30 min. The coverslips were then 
immersed in primary antibodies diluted in 5% BSA in PBS followed by secondary 
immunofluorescent antibodies diluted in 5% BSA in PBS. Nuclei were stained with 
Hoechst 33342 (Invitrogen Molecular Probes). The Coverslips were mounted onto 
slides using Fluoromount/Plus mounting solution (Diagnostic BioSystems) and images 
were obtained using a fluorescent microscope (Keyence: Model BZ-9000).  
Fluorescence Analysis 
HeLa cells cultured on coverslips were transfected with fluorescent protein 
tagged-plasmids. The cells were incubated in 1 mM Hoechst 33342 (Invitrogen 
Molecular Probes) diluted in culture media, for 10 min. The cells were then washed 
with PBS, fixed with 4% paraformaldehyde in PBS for 10 min, and mounted onto slides 
using Fluoromount/Plus mounting solution (Diagnostic BioSystems). Images were 
obtained using a fluorescent microscope (Keyence: Model BZ-9000). 
In vitro Ubiquitination Assay 
Cul3-KLHL7 complex was immunoprecipitated from cells expressing FLAG-KLHL7 
and eluted in 1x FLAG peptide (Sigma) in TBS. The purified protein was incubated at 
30°C for 1 or 2 hour with 10 µg of Ub (Sigma), 0.2 µl of Ub-activating enzyme UBE1 
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(Boston Biochem), 0.2 µg of Ub-conjugating enzyme His-Ubc4 purified from E. Coli, 
in reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 0.5 mM 
DTT) either with or without 5 mM ATP at the final volume of 50 µl. The reaction was 
stopped by the addition of SDS sample buffer, followed by boiling for 5 min at 100°C. 
The reaction mixtures were then subjected to Immunoblot analyses with anti-multi-Ub 
(MBL: FK2) antibody to assess poly-Ub chain formation. 
Homology Modeling and Sequence Alignment 
Homology models of Cul3, KLHL7 (wild-type and mutants) were generated using the 
SWISS-MODEL automated mode (http://swissmodel.expasy.org/)4,8,42,65. The 
superimposition and editing of the models were done using PyMOL software 
(http://www.pymol.org/)74. Sequence alignments were done using the CLUSTALW 
(http://www.genome.jp/tools/clustalw/)80.   
11
1.4 RESULTS 
KLHL7 forms Cullin3-based complex. 
Some BTB proteins have been reported to function as the substrate recognition subunits 
of Cul3-based CRLs. However, whether KLHL7 associates with Cul3 or functions as an 
E3 ligase has been unknown. To investigate whether KLHL7 forms Cul3-based 
complex, FLAG-tagged KLHL7 was expressed in HCT116 cells and 
immunoprecipitated FLAG-KLHL7 from the cell lysates using the anti-FLAG antibody. 
As shown in Figure 1, Cul3 and Roc1 were co-immunoprecipitated with FLAG-KLHL7, 
indicating that KLHL7 forms Cul3-complex. 
To characterize the domain of KLHL7 involved in the interaction with Cul3, 
KLHL7 mutants lacking each domain were constructed (Figure 2A). Wild-type KLHL7 
(Figure 2B, lane 1) and the mutant lacking the Kelch domain, which still has the BTB 
and BACK domains (Figure 2B, lane 5), were able to bind to Cul3. On the other hand, 
the ΔBTB, ΔBTB-BACK and ΔBACK mutants lacking either or both the BTB and the 
BACK domains could not (Figure 2B, lanes 2-4). These results suggest that KLHL7 
associates with Cul3 via the BTB and BACK domains and both are required for Cul3 
binding. The amount of Cul3 that co-immunoprecipitated with the Δ Kelch was greater 
than that of wild-type KLHL7 (lanes 1 and 5), which may reflect the decrease in 
interacting partners by the deletion of the Kelch domain, resulting in the increase in the 
interacting ratio of Cul3. 
To examine the sub-cellular localization of KLHL7 and Cul3, HeLa cells 
transfected with FLAG-KLHL7 and HA-Cul3 were subjected to immunocytochemical 
analyses. As shown in Figure 3, KLHL7 was mostly present as punctate structures, 
which were also positive for Cul3 staining. While most of KLHL7 co-localized with 
Cul3, not all of the Cul3 positive signals stained positive for KLHL7, suggesting that 
only a subset of Cul3 is associated with KLHL7. Furthermore the punctate structures 
were not formed by any of the deletion mutants including the ΔKelch mutant (Figure 4), 
indicating that Cul3 interaction is not sufficient for punctate formation. These results 
indicate that KLHL7 co-localizes with Cul3, and all of the domains are necessary for 
the punctate sub-cellular localization. 
KLHL7 forms a homo dimer through its BTB domain. 
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Several members of the BTB family proteins, such as Keap1 and SPOP, form homo- 
dimers60,99. To investigate whether KLHL7 dimerizes, HA-tagged wild-type KLHL7 
was co-expressed with FLAG-tagged KLHL7 wild-type or deletion mutants into 
HCT116 cells and their interactions were assessed. Immunoprecipitation experiments 
showed that wild-type KLHL7 is able to homo dimerize (Figure 5, lane 1). The ΔBACK 
and ΔKelch mutants still interacted with wild-type KLHL7 (lanes 4 and 5), whereas 
deletion of the BTB domain led to weak interaction (lane 2), which was further 
weakened by the additional deletion of the BACK domain (lane 3). These results 
suggest that the BTB domain is the primary domain necessary for KLHL7 dimerization, 
while the BACK domain, which is not essential for dimerization, is important for 
efficient dimerization. Because the ΔBACK mutant that could not interact with 
Cul3 (Figure 2B) was still able to dimerize (Figure 5), the dimer formation of KLHL7 is 
not mediated indirectly by Cul3 interaction. 
Cul3-KLHL7 has Ub ligase activity. 
Because KLHL7 forms Cul3-based complexes, the Ub ligase activity of the 
Cul3-KLHL7 was investigated. If KLHL7 is indeed a part of a Ub ligase complex, the 
substrates of KLHL7 should accumulate in the ubiquitinated form when the proteasome 
is inhibited. To test this, HCT116 cells were transfected with FLAG-KLHL7 and 
HA-Ub and treated with the proteasome inhibitor MG132 prior to immunoprecipitation. 
Immunoblot analyses with anti-HA antibody showed that ubiquitinated proteins interact 
with FLAG-KLHL7, the amount of which increased drastically with proteasome 
inhibition (Figure 6A). These data suggest that the ubiquitinated proteins that interacted 
with KLHL7 are targeted for proteasome degradation. As strong bands were observed at 
the predicted molecular weight of ubiquitinated KLHL7 (approx. 70 Kd), it may be 
possible that KLHL7 itself is a target. On the other hand, ubiquitin positive bands were 
also observed below the predicted molecular weight of ubiquitinated KLHL7, 
suggesting that those ubiquitinated proteins represent the authentic substrates of 
KLHL7.   
To investigate whether KLHL7 is indeed self-ubiquitinated, the ubiquitination 
state of KLHL7 was examined by detecting FLAG-KLHL7 after HA-Ub 
immunoprecipitation. After proteasome inhibition, cell lysates of HCT116 cells 
expressing HA-Ub and FLAG-KLHL7 were immunoprecipitated with anti-HA antibody, 
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and subsequently immunoblotted with anti-FLAG antibody to detect ubiquitinated 
KLHL7 (Figure 6B). A single band of the estimated molecular weight of 
mono-ubiquitinated KLHL7 was strongly detected, whereas no ladder or smear was 
observed, indicating that the majority of KLHL7 are only present as the 
mono-ubiquitinated form. These results suggest that the increase of Ub moiety 
associated with KLHL7 upon proteasome inhibition is mostly due to the accumulation 
of poly-ubiquitinated authentic substrates. 
Next, the ligase activity of Cul3-KLHL7 was examined, in a 
substrate-independent in vitro ubiquitination assay62,77. Cul3-KLHL7, purified from 
HCT116 cells by immunoprecipitation, was incubated with Ub activating enzyme E1, 
Ub conjugating enzyme E2 and Ub in buffers with or without ATP (Figure 6C). The 
amount of poly-Ub chain, observed as smears of higher molecular weight, increased in a 
time dependent manner, in the presence of ATP, indicating that Cul3-KLHL7 has E3 
ligase activity. 
Ub positive KLHL7 puncta increase with proteasome inhibition.  
KLHL7 and Cul3 co-localized in punctate structures in the cytoplasm (Figure 3). 
KLHL7 also interacted with Ub, which increased with proteasome inhibition (Figure 
6A). Therefore it was investigated whether the KLHL7 puncta co-localize with Ub upon 
proteasome inhibition. Immunocytochemical analyses using the FK2 anti-multi-Ub 
antibody, which recognizes poly-Ub chains and poly-ubiquitinated substrates, indicated 
that KLHL7 co-localized with ubiquitinated proteins, and the co-localizing structures 
increased with proteasome inhibition (Figure 7A). Similarly, co-localization of KLHL7 
with Lys48-linked Ub chain increased with proteasome inhibition when detected with 
the Lys48-linked Ub chain specific antibody (Figure 7B). On the other hand, no 
co-localization of KLHL7 with Lys63-linked Ub was seen, regardless of proteasome 
inhibition (Figure 7C). These results show that KLHL7 co-localizes with Lys48-linked 
poly-ubiquitinated proteins, but not with those with Lys63-linked poly-ubiquitin, 
suggesting that KLHL7 mediates the linkage of Lys48-linked, but not Lys63-linked 
poly-ubiquitin chain onto target proteins. The increase in Poly-Ub and Lys48-linked-Ub 
positive KLHL7 puncta with proteasome inhibition, indicate that the substrates 
ubiquitinated by KLHL7 are targeted for proteasomal degradation. 
Ubiquitinated proteins can also be processed by the lysosome through the 
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autophagic pathway48. To investigate if the substrate of KLHL7 is also degraded by the 
lysosome, the co-localization of KLHL7 and Ub were examined under NH4Cl treatment 
(Figure 8A and B). In contrast to proteasome inhibition, no accumulation in Ub positive 
KLHL7 puncta was seen with lysosome inhibition with NH4Cl. Moreover, when 
GFP-tagged KLHL7 was co-expressed with mCherry tagged LAMP1, the lysosome 
marker, the KLHL7 punctates did not co-localize with LAMP1, either with or without 
lysosome inhibition with NH4Cl (Figure 9). 
Furthermore, the involvement of the autophagic pathway was assessed by the 
co-localization of KLHL7 with GFP-tagged autophagosome marker LC3 using 
ATG5+/+: GFP-LC3 and autophagy deficient ATG5-/-: GFP-LC3 MEFs. No increase in 
the co-localization of KLHL7 with GFP-LC3 was observed with MG132 or NH4Cl 
treatment, regardless of the increase in GFP-LC3 dots with lysosome inhibition (Figure 
10). Taken together, these data suggest that KLHL7-associated ubiquitinated proteins 
are processed mostly, if not all, by the proteasome, and not the lysosome or 
LC3-dependent autophagy. 
AdRP causing A153V and A153T mutations disrupt Cul3 interaction but not 
dimerization. 
Recently, three missense mutations, S150N, A153T and A153V in KLHL7 were found 
in patients with adRP25. All of these mutations are in the BACK domain, and while both 
S150 and A153 are conserved within vertebrate KLHL7 (Figure 11A), only A153 is 
conserved within other human BTB-BACK-Kelch proteins (Figure 11B). As the BACK 
domain is necessary for the interaction with Cul3 but not for KLHL7 dimerization 
(Figures 2A and 5), whether these mutants interact with Cul3 was examined in HCT116 
cells. KLHL7 S150N was able to still interact with Cul3 (Figure 12, lane 4), whereas 
the A153V and A153T mutants could not (Figure 12, lanes 2 and 3). I also investigated 
the sub-cellular localization of these missense mutations and their co-localization with 
Cul3. Immunocytochemical analyses in HeLa cells showed that KLHL7 S150N had 
similar sub-cellular localization with wild-type KLHL7 and co-localized with Cul3 
(Figure 13B top). On the contrary, the sub-cellular localization of A153V and A153T 
was more peripheral than that of wild-type KLHL7, and co-localization with Cul3 was 
not as prominent (Figures 3 and 13, A and B bottom). Taken together, these data 
suggest that A153 mutations in KLHL7 attenuate its interaction and co-localization with 
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Cul3. 
To examine if the mutations in the A153 position affects the dimerization 
ability of KLHL7 by using the A153V mutant, as the BACK domain was important for 
efficient dimerization (Figure 5), FLAG-KLHL7 wild-type or A153V with HA-KLHL7 
wild-type or A153V was expressed in HCT116 cells and immunoprecipitated the cell 
lysates with anti-FLAG antibody. KLHL7 A153V was able to form both a homo dimer, 
and a hetero dimer with wild-type KLHL7 (Figure 14A). The S150N and A153T 
mutants could also bind to wild-type KLHL7 (Figure 14B). These data suggest that 
none of the adRP causative mutations interfere with KLHL7 dimerization. 
Immunocytochemical analyses showed that when both wild-type KLHL7 and A153V 
were expressed in HeLa cells, co-localization was observed in peri-nuclear punctate 
structures, resembling the sub-cellular localization of wild-type KLHL7 (Figure 14C). 
These data indicate that the sub-cellular localization of KLHL7 A153V seems to be 
restored to that of wild-type KLHL7 by forming a hetero dimer. 
KLHL7 A153V does not inhibit Cul3-wild-type KLHL7 interaction. 
As KLHL7 A153V associates with wild-type KLHL7 but not directly with Cul3, 
whether or not the hetero dimerization of KLHL7 A153V with wild-type KLHL7 
inhibits the formation of Cul3-KLHL7 complex was investigated. KLHL7 A153V was 
co-expressed with wild-type KLHL7 and the amount of Cul3 that 
co-immunoprecipitated with wild-type KLHL7 was investigated (Figure 15). The 
co-immunoprecipitation of Cul3 with wild-type KLHL7 did not decrease even when 
KLHL7 A153V was co-expressed (Figure 15, FLAG IP lanes 2 and 3). Moreover, a 
slight amount of Cul3 was co-immunoprecipitated by KLHL7 A153V when the 
wild-type KLHL7 was also co-expressed (Figure 15, HA IP lanes 1 and 3). Similarly, 
A153T was also able to associate with Cul3 by the co-expression of wild-type KLHL7 
(Figure 16). Taken together, it seems that though KLHL7 A153V cannot directly 
interact with Cul3, the mutation in one molecule of the KLHL7 dimer does not inhibit 
the assembly of Cul3-KLHL7 in a dominant negative manner. 
KLHL7 A153V attenuates the E3 Ligase activity of Cul3-KLHL7. 
To understand the effect of KLHL7 with mutations in A153 in the Cul3-KLHL7 
complex, whether or not the incorporation of KLHL7 A153V affects the E3 ligase 
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activity of Cul3-KLHL7 was investigated. FLAG-KLHL7 and HA-Ub were transfected 
with increasing amounts of 6Myc-KLHL7 A153V, and ubiquitinated proteins 
associated with FLAG-KLHL7 were examined. Under proteasome inhibition, the 
amount of Ub that associated with wild-type KLHL7 decreased in proportion to the 
co-expressed KLHL7 A153V, even though there was no change in the amount of 
co-immunoprecipitated Cul3 and FLAG-KLHL7 (Figure 17). These data indicate that 
the A153V mutant inhibits the E3 activity of Cul3-KLHL7. 
S150 and A153 are located near the Cul3 interacting surfaces of KLHL7. 
The structures of Cul3 and the BTB-BACK domain of KLHL7 are unknown. Therefore, 
to clarify the structural effects the mutations have on KLHL7, homology-based 
structural models of KLHL7 and Cul3 were generated, using the SWISS-MODEL 
workspace, automated mode4,8,42,65. 
The BTB-BACK domain of KLHL7 was modeled on the X-Ray diffraction 
model of SPOP (PDB ID: 3hqi, Chain ID: A) (Figure 18) and Cul3 was modeled on the 
X-Ray diffraction model of Cul1 (PDB ID: 1ldj, Chain ID: A) (Figure 19). The models 
were superimposed on the Skp1-Cul1 domain (PDB ID: 1ldj) to obtain hypothetical 
KLHL7-Cul3 conformations, and on the model of KLHL11 dimer model (PDB ID: 
313N) to obtain hypothetical KLHL7 dimer models (Figure 20).  
When the positions of the mutated residues, S150 and A153 was predicted, 
they were located in the middle of an alpha-helix of one of the 3-box helix fingers 
(Figure 20), which is important for the correct association and positioning of BTB 
proteins and Cul3. The three helices of the 3-box region are not on the binding surface, 
but on the neighboring regions that lie over the N-terminus side of Cul3, and cup around 
the end of the crescent shape. Moreover, these two amino acids did not localize in or 
near the dimerization surfaces of KLHL7. These results suggest the involvement of 
these amino acids in Cul3 interaction but not dimerization, and support the experimental 
results, that the A153 mutations inhibit Cul3 interaction but not dimerization of 
KLHL7.  
A153T and A153V mutations may lead to structural alteration of the 3-box of 
KLHL7. 
As S150 and A153 are located near the Cul3-interacting regions, the possible effects of 
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the amino acid substitutions on the structure of KLHL7 was investigated. The 
homology-based models of KLHL7 mutants and predicted changes in the amino acid 
side chains brought on by the missense mutations were re-generated (Figure 21). The 
substitution of A153 to V or T led to slightly bulkier side chains that stuck outwards 
from the helix in the direction of the adjacent helix. This change in the protrusion of 
side chains may cause a wider positioning of the helices, hindering the correct 
structuring of this region. 
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1.5 Discussion 
This study shows that KLHL7 dimerizes and forms a novel Cul3-based E3 ligase. 
Though the RP causative KLHL7 S150N mutant did not have obvious effects, and 
remains to be further investigated, this study provides insights into how the A153 
mutations affect the ligase activity of Cul3-KLHL7. The A153V and A153T mutants 
have the putative substrate binding Kelch, and the dimerization BTB domains intact. 
Therefore it is conceivable that the homo dimers are able to bind onto its authentic 
substrates. As the A153 mutants could not directly associate nor co-localize with Cul3, 
the substrate bound to the mutant homo dimer would not be recruited to the Cul3-Roc1 
complex for ubiquitination (Figure 22, right). The sub-cellular localization of A153V 
and A153T mutants differed from that of wild-type, suggesting that the subcellular 
localization of KLHL7 is affected by Cul3-binding and subsequent ubiquitination of 
substrates. Consistent with this notion, none of the deletion mutants formed such 
punctate structures (Figure 4), including the ΔKelch mutant that associates with Cul3. 
Although KLHL7 A153V and A153T did not interact with Cul3, 
co-expression of wild-type KLHL7 enabled the mutants to associate with Cul3. 
Furthermore, the localization of KLHL7 A153V returned to normal appearance with the 
co-expression of wild-type KLHL7. These results suggest that the mutants can be 
incorporated into the Cul3 complex through the dimerization with wild-type KLHL7. 
However, the amount of ubiquitinated proteins associated with Cul3-KLHL7 greatly 
diminished when the A153V mutant was present in the complex (Figure 17). This 
suggests that KLHL7 A153V mutant inhibits the ligase activity of Cul3-KLHL7, which 
can be attributed to the change in the conformation of the complex. As the hetero dimer 
would only be able to recruit one molecule of Cul3 with the wild-type KLHL7, the 
overall number of the catalytic subunit Roc1 incorporated in the Cul3-KLHL7 complex 
will decrease (Figure 22, left and middle). Several previous studies have also shown that 
CRLs take dynamic conformations, the flexibility of which may be rate limiting for 
ligase activity21,57. Dimerization of substrate recognition proteins may influence the 
positioning of the substrate within the complex, as suggested by the analysis of the 
F-box protein Cdc4. The dimerization of Cdc4 does not influence the affinity with its 
substrate Sic1, but seems to influence the positioning of the substrate within the ligase 
complex78. KLHL7 may function likewise, and the incorporation of the A153 mutant, 
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which potentially harbors bulky side chains that is predicted to interfere with complex 
formation, into the Cul3-KLHL7 complex may result in a change in the flexibility or the 
correct positioning of the substrate, necessary for efficient substrate ubiquitination. The 
attenuation of Cul3-KLHL7 ligase activity by homo and hetero dimers of mutant 
KLHL7, will lead to the decrease in substrate ubiquitination, which could result in their 
accumulation or changes in their functions, leading to cellular toxicity. 
Cul3-KLHL7 formed punctate structures that resemble vesicles or inclusion 
bodies. Inclusion bodies, which secludes misfolded or unnecessary proteins, are 
degraded by the proteasome and autophagic pathways48. In this study, Lys48-linked 
poly-Ub positive KLHL7 puncta, increased with proteasome inhibition, suggesting that 
proteins ubiquitinated by Cul3-KLHL7 are degraded by the proteasome. On the other 
hand, the puncta did not increase with NH4Cl treatment (Figure 8) nor co-localize with 
the lysosome marker LAMP1 (Figure 9) and the autophagosome marker LC3 (Figure 
10), making it unlikely that these puncta are processed by the lysosomal pathway. 
RP is a heterogeneous disease, which is caused by defects in different 
biochemical cascades18,31. To date, more than 45 genes responsible for RP have been 
found, of which approximately 20 genes are known to be responsible for adRP. 
Mutations in membrane proteins such as RDS and the photon receptor RHO are known 
to cause RP. Several genes related to protein trafficking and the cytoskeletal structures, 
such as FSCN2, that binds to actin73,83 and microtubule associated RP151, as well as 
MYO7A involved in intracellular trafficking23,85,88, have also been reported as RP 
causative genes. Ub modification is known to be important for the quality control, 
internalization and multivesicular-body sorting of membrane proteins. It is also 
involved in the regulation of vesicle sorting and transport along the cytoskeletal 
structures30,72. In this research, I focused on the functions of KLHL7 in the 
ubiquitination of degradation processes. Nevertheless, KLHL7 may still be involved in 
the regulation of any of these processes, however, how it is involved remains to be 
elucidated. 
In summary, I present KLHL7 as a novel substrate recognition subunit of 
Cul3-based Ub ligase complex. Moreover, I have shown that the adRP causative A153V 
mutation inhibits the ligase activity of Cul3-KLHL7 in a dominant negative manner.
These results confirm the initial perception that the conformation of the CRL is 
important for its activity. Furthermore, the fact that KLHL7 A153V inhibits the activity 
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of Cul3-KLHL7, thereby exhibiting a dominant negative effect on Cul3-KLHL7, 
implies the necessity of two Cullin and two Roc1 molecules in a single complex for its 
activity. 
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Figure 1. KLHL7 forms a Cul3-based complex. 
HCT116 cells transfected with FLAG-KLHL7 or mock vectors were 
immunoprecipitated with anti-FLAG antibody and immunoblotted with antibodies to 
Cul3, Roc1, and FLAG. 
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    B 
Figure 2. The BTB and BACK domains of KLHL7 are necessary for Cul3 
interaction. 
A, Schematic representations of KLHL7 (wild-type and deletion mutants) used in this 
study. Expected molecular weights are indicated on the left (kDa). 
B, Deletion mutants of FLAG-tagged KLHL7 were expressed in HCT116 cells and 
immunoprecipitated with anti-FLAG antibody, and immunoblotted with anti-Cul3 and 
anti-FLAG antibodies. Non-specific IgG bands are indicated with an asterisk (*). 
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Figure 3. KLHL7 co-localizes with Cul3 in Punctate Structures. 
HeLa cells cultured on coverslips were transfected with HA-Cul3 and FLAG-KLHL7. 
The cells were fixed and stained with anti-HA and anti-FLAG antibodies and Hoechst 
33342. Scale bar, 20 µm. 
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Figure 4. KLHL7 deletion mutants do not form punctate structures in the cell.  
HeLa cells cultured on coverslips were transfected with FLAG-KLHL7 wild-type or 
deletion mutants. The cells were fixed and stained with anti-FLAG antibody and 
Hoechst33342. Scale bars, 20 µm. 
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Figure 5. The BTB domain is necessary for KLHL7 dimerization. 
Deletion mutants of FLAG-tagged KLHL7 were co-expressed with HA-tagged full 
length KLHL7 in HCT116 cells and immunoprecipitated with anti-FLAG and anti-HA 
antibodies. The immunoprecipitates were blotted with anti-HA and anti-FLAG 
antibodies. 
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Figure 7. The Ub positive KLHL7 puncta increase with proteasome inhibition.  
A, B and C. HeLa cells cultured on coverslips were transfected with FLAG-KLHL7 and 
treated with either 20 µM of MG132 or DMSO and stained with antibodies to FLAG 
(red) and Ub (green) with anti-FK2 (A), anti-K48 (B) and anti-K63 (C). The nucleus 
was stained with Hoechst 33342. Scale bars, 20 µm.  
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Figure 8. Ub positive KLHL7 puncta do not increase by lysosome inhibition.  
A, B. HeLa cells cultured on coverslips were transfected with FLAG-KLHL7 and 
treated with or without NH4Cl for lysosome inhibition and stained with antibodies to 
FLAG and Ub with anti-FK2 (A) and anti-K48 (B). The nucleus was detected with 
Hoechst 33342. Scale bars, 20 µm. 
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Figure 9. KLHL7 does not co-localize with the Lysosome marker LAMP1. 
HeLa cells cultured on coverslips were transfected with GFP-KLHL7 and 
mCherry-LAMP1 and treated with or without NH4Cl for lysosome inhibition. The cells 
were fixed and observed, following nucleus staining with Hoechst 33342. Scale bars, 20 
µm. 
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Figure 10. KLHL7 co-localization with GFP-LC3 does not increase with 
proteasome or lysosome inhibition.  
ATG5+/+:GFP-LC3 and ATG5-/-:GFP-LC3 MEFs expressing FLAG-KLHL7 were 
subjected to proteasome inhibition with MG132 or lysosme inhibition with NH4Cl and 
stained with anti-FLAG and anti-GFP antibodies. The nucleus was stained with 
Hoechst 33342. Scale bars, 20 µm. 
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Figure 12. KLHL7 A153 mutations inhibit Cul3 interaction. 
HCT116 cells were transfected with either FLAG-KLHL7 wild-type or missense 
mutants. The cell lysates were immunoprecipitated with anti-FLAG antibody and 
immunoblotted with anti-Cul3 and anti-FLAG antibodies. Protein levels were 
determined by densitometric quantification of immunoblots and relative Cul3 levels are 
shown. 
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Figure 13. KLHL7 S150N co-localizes with Cul3, but A153 mutants do not. 
A, B. HeLa cells cultured on coverslips were transfected with HA-Cul3 and 
FLAG-KLHL7 A153V (A) or GFP-Cul3 with FLAG-KLHL7 S150N or A153T (B). 
The cells were fixed and stained with anti-FLAG and anti-HA (A) or anti-GFP (B) 
antibodies. The nucleus was stained with Hoechst 33342. Scale bars, 20 µm.
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Figure 14. S150 and A153 mutants dimerize with KLHL7. 
A. FLAG-KLHL7 (wild-type (WT) and A153V (mt)) and HA-KLHL7 (wild-type (WT) 
and A153V (mt)) were expressed in HCT116 cells as indicated. FLAG-KLHL7 was 
immunoprecipitated with anti-FLAG antibody and immunoblotted with anti-HA and 
anti-FLAG antibodies.  
B. HCT116 cells were transfected with FLAG-KLHL7 S150N or A153T with 
Myc-KLHL7 wild-type and the cell lysates were immunoprecipitated with anti-FLAG 
antibody. The immunoprecipitates were immunoblotted with anti-Myc and anti-FLAG 
antibodies. 
C. HeLa cells on coverslips were transfected with FLAG-KLHL7 and HA-KLHL7 
A153V. After fixation, cells were stained with anti-FLAG and anti-HA antibodies and 
Hoechst 33342. Scale bar, 20 µm. 
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Figure 15. A153V mutation does not inhibit KLHL7 wild-type interaction with 
Cul3. 
HCT116 cells were transfected with FLAG-KLHL7 and HA-KLHL7 A153V as 
indicated. The cell lysates were immunoprecipitated with anti-FLAG or anti-HA 
antibodies and immunoblotted with anti-Cul3, anti-HA and anti-FLAG antibodies. 
79
 
 
 
 
 
 
 
 
 
 
 
Figure 16. KLHL7 A153T associates with Cul3 through hetero dimerization with 
wild-type KLHL7. 
HCT116 cells were transfected with FLAG-KLHL7 A153T and Myc-KLHL7, as 
indicated. The cell lysates were immunoprecipitated with anti-FLAG antibody and 
immunoblotted with anti-Cul3, anti-Myc and anti-FLAG antibodies. 
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Figure 17. KLHL7 A153V attenuates Cul3-KLHL7 ligase activity.  
HCT116 cells were transfected with FLAG-KLHL7, HA-Ub, and increasing amounts of 
6Myc-KLHL7 A153V. The cells were treated with 20 µM MG132 for 1 hr prior to 
harvesting and immunoprecipitated with anti-FLAG antibodies. Immunoblot analyses 
were done using anti-HA, anti-Myc, anti-Cul3, and anti-FLAG antibodies.  
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Figure 18. Homology-model of KLHL7. 
The homology-model of the BTB-BACK domain of KLHL7 is indicated in magenta, 
and the template structure model of SPOP is shown in green. 
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Figure 19. Homology-model of Cul3. 
The homology-model of Cul3, and the template structure model of Cul1 are shown in 
green and blue, respectively. 
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Figure 20. Hypothetical conformation of KLHL7 dimer and Cul3. 
Superimposed conformation of a KLHL7 homo dimer and one molecule of Cul3. Each 
KLHL7 molecule is colored in different shades of green, and the Cul3 molecule 
associated with the darker KLHL7 is shown as pale blue. The positions of the 3-box 
helix fingers, each helix are as labeled, and the positions of S150 and A153 are 
indicated in orange and red respectively. 
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Figure 21. A153V and A153T amino-acid substitution results in bulkier side 
chains. 
Homology model of the 3-box helices of KLHL7 WT (A), A153V (B) and A153T (C). 
The side chains of the 153rd amino acid are indicated in red or magenta. An adjacent 
loop structure connecting the two helices on the top of each panel has been removed for 
a clearer view. The numbers of each helix of the 3-box region are labeled as in Figure 
20. 
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Figure 22. Molecular models of KLHL7-mediated ubiquitination.  
KLHL7 is indicated in bright red: wild-type and dark red: A153V or A153T, and the 
substrate as S. The domains of KLHL7 are indicated as BB: BTB, BK: BACK and Klh: 
Kelch. The wild-type KLHL7 homo dimer binds to two sets of Cul3/Roc and targets the 
substrates for ubiquitination (left). The hetero dimer of wild-type and A153 mutant can 
only bind to one set of Cul3/Roc1, and may ubiquitinate one of the two substrates, if not 
at all (middle). The A153 mutant homo dimer cannot bind to Cul3/Roc1 and fails to 
target the substrates for ubiquitination (right).  
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